FREDERICK, Md., March 29, 2016 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of the drug-free over-the-counter, $30.00 ActiPatch® (www.actipatch.com) Musculoskeletal Pain Therapy medical devices, announced today the completion of a 6-month ActiPatch product observation study conducted in conjunction with its ongoing market research.
The study was conducted to measure the medical device's pain relief durability, its reduction of pain medication use, including prescription narcotic drugs, and its impact on the user's quality of life.
Out of the 254 chronic pain sufferers that participated, 224 completed the full 6-month study.
The key findings:
The study has been accepted and will be presented at the British Pain Society annual scientific meeting being held from May 10-12 in Harrogate, UK https://www.britishpainsociety.org/2016-asm/. The Company will also be exhibiting at the Congress: Booth #42.
About BioElectronics Corporation
BioElectronics Corporation (www.bielcorp.com) is a leader in non-invasive electroceutical and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy; and HealFast® Therapy for dogs, cats and horses.
Contact:
Paul Knopick
940.262.3584
pknopick@eandecommunications.com
SOURCE BioElectronics Corporation